PNPLA3 rs738409 underlies treatment response in nonalcoholic fatty liver disease

Jin-Zhi Wang, Hai-Xia Cao, Jian-Neng Chen, Qin Pan

Received: April 24, 2018  
Peer-review started: April 24, 2018  
First decision: May 11, 2018  
Revised: May 16, 2018  
Accepted: June 7, 2018  
Article in press: June 8, 2018  
Published online: August 16, 2018

Abstract

Non-alcoholic fatty liver disease (NAFLD) has now become the leading cause of chronic liver disease with its growing incidence worldwide. Patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 C > G reflects one of the critical genetic factors that confers high-risk to NAFLD. However, the role of PNPLA3 polymorphism in NAFLD treatment remains uncertain. Here, the present review reveals that NAFLD patients with G-allele at PNPLA3 rs738409 (PNPLA3 148M variant) are sensitive to therapies of lifestyle modification, dipeptidyl peptidase-4 inhibitors, and bariatric surgery. They exhibit much significant reduction of liver fat content, in concurrence with weight loss and abolished insulin resistance, as compared to those of C-allele carriers. In contrast, patients bearing PNPLA3 rs738409 C-allele (PNPLA3 148I variant), instead of G-allele, demonstrate greater beneficial effects by omega-3 polyunsaturated fatty acids and statin intervention. Improved adipose tissue-liver interaction and decrease in intrahepatic triglyceride efflux may contribute to the PNPLA3 rs738409 related diversities in therapeutic efficacy. Therefore, PNPLA3 rs738409 underlies the response to a variety of treatments, which warrants a personalized, precise medicine in NAFLD on the basis of genotype stratification.

Key words: Non-alcoholic fatty liver disease; Patatin-like phospholipase domain-containing protein 3; Treatment; Lifestyle; Pharmacotherapy; Surgery; Polymorphism
Core tip: Patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 imposes universal, yet distinctly different, impact on various therapies in nonalcoholic fatty liver disease (NAFLD) patients. As compared to those with C-allele, patients with PNPLA3 rs738409 G-allele (PNPLA3 148M variant) show greater improvement in response to lifestyle modification, dipeptidyl peptidase-4 inhibitor ingestion, and bariatric surgery. In contrast, NAFLD patients carrying PNPLA3 rs738409 C-allele (PNPLA3 148I variant) are much sensitive to both omega-3 polyunsaturated fatty acids and statin intervention. These diversities in treatment response warrant a personalized, precise medicine in NAFLD by stratification of PNPLA3 rs738409 genotype.

INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD), a metabolic stress-induced chronic liver disease, has undergone a dramatic increase in prevalence worldwide over the last few decades with a morbidity rate of 15%-40%[3,4]. Over 20% of NAFLD patients progress from simple steatosis to non-alcoholic steatohepatitis (NASH)[3,4], which has a >10% chance of developing into liver fibrosis/cirrhosis and even hepatocellular carcinoma[5]. Due to the considerable burden of NAFLD on public health, it has become an emergent target for clinical intervention.

In addition to a sedentary lifestyle and Western diet, genetic polymorphism of various genes is considered as the other important factor in NAFLD predisposition[6]. In a genome-wide association scan (GWAS) of nonsynonymous sequence variations (n = 9229), patatin-like phospholipase domain-containing protein 3 (PNPLA3) rs738409 C > G (PNPLA3 1148M) was identified as a risk factor for NAFLD in Hispanic, African American and European Americans[7]. Further studies in multiple ethnic populations confirmed the effect of PNPLA3 1148M on NAFLD susceptibility, with a spectrum ranging from steatosis, NASH, to liver fibrosis[8-11]. PNPLA3 encodes the adiponutrin which is sited in the endoplasmic reticulum and on lipid droplets in hepatocytes. Possessing a patatin-like domain at the N-terminal, PNPLA3 shows hydrolase activity against glycerolipids (triaclyglycerol, diacylglycerol, and monacylglycerol), and has a crucial role in the homeostasis of lipid metabolism[12,13]. However, PNPLA3 148M functions in a “loss-of-function” way and leads to low levels of glycerolipid hydrolysis in the liver and inhibition of lipid outflow to peripheral adipose tissues[12,13]. Therefore, the PNPLA3 148M variant contributes to hepatic steatosis and related disorders depending on its interference with lipometabolic balance.

Current therapeutic approaches for NAFLD include lifestyle modification (e.g., diet therapy and physical activity)[14,15], pharmacotherapy [e.g., omega-3 fatty acids, statins, and dipeptidyl peptidase-4 (DPP-4) inhibitors][16], and bariatric surgery (e.g., nonadjustable or adjustable banding, vertical banded gastroplasty, and gastric bypass)[17]. It is rational to propose that PNPLA3 rs738409 C > G (PNPLA3 148M) may affect the efficacy of NAFLD therapy due to the disturbance of glycerolipid-metabolic homeostasis. In this review, we summarize the therapeutic outcomes in NAFLD patients with different genetic backgrounds in order to highlight the interaction between PNPLA3 genotypes and treatment response.

LIFESTYLE MODIFICATION

Lifestyle modification, including a hypocaloric diet and/or increased physical activity, has been recommended as first-line therapy by the Diagnosis and Management of NAFLD practice guideline[18]. To test the effects of PNPLA3 polymorphism on treatment response to lifestyle modification, a randomized controlled trial was conducted in 154 adult Hong Kong residents with NAFLD[19]. Following equal randomization into the intervention and control group, respectively, 77 NAFLD patients received dietary consultation sessions that encouraged an individual-designed menu with emphasis on fruit and vegetables, and moderate-carbohydrate, low-fat, low-glycemic index, and low-caloric products in appropriate portions according to the recommendations of the American Dietetic Association. In addition, the patients were instructed to develop a routine exercise habit (30 min every day). Evaluation of these patients using proton magnetic resonance spectroscopy (1H-MRS) showed that NAFLD patients carrying the G-allele at PNPLA3 rs738409 demonstrated a greater reduction in intrahepatic triglyceride content (IHTG) (GG: 11.3 ± 8.8%) compared to those with the C-allele (CC: 3.7 ± 5.2%, CG: 6.5 ± 3.6%) at the end of the 12-mo treatment. A greater decrease in body weight, waist-to-hip ratio (WHR), total cholesterol (TC), and low-density lipoprotein (LDL) cholesterol was also confirmed in the G-allele, but not the C-allele carriers with the exception of biochemical liver stiffness measurements. The reduction in hepatic fat was parallel with the decrease in body weight and improvement in LDL cholesterol and TC. Multivariate analysis showed that PNPLA3 genotype and body mass index (BMI) change were the only factors correlated with IHTG reduction in the intervention group. In contrast, no correlations between PNPLA3 rs738409 and changes in IHTG or other measured parameters were found in the control group.

Eight subjects with a homozygous PNPLA3 rs738409...
G-allele (PNPLA3-148MM) and 10 with a homozygous PNPLA3 rs738409 C-allele (PNPLA3-148II) were recruited for a further 6-d trial of a hypocaloric (1000-kcal deficit/d), low-carbohydrate diet (< 30 g/d). Despite a similar percentage of liver fat as shown by 1H-MRS on day 0, the PNPLA3-148MM group experienced a significantly greater reduction in liver fat than the PNPLA3-148II group (day 6, PNPLA3-148MM vs PNPLA3-148II: 10.2 ± 1.8% vs 11.9 ± 2.1%) independent of a comparable weight loss. In this study, no statistical differences were found in plasma alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyltransferase (GGT), and free fatty acid (FFA) concentrations between the two groups. It is necessary for individuals with NAFLD to achieve amelioration of steatosis by a 3%-5% weight loss, and to achieve an improvement in necroinflammation of up to 10%[18, 20]. Thus, the incomplete response to diet therapy may be due to an inadequate weight reduction (-3.7 ± 0.5% in the PNPLA3-148MM group, -3.3 ± 0.3% in the PNPLA3-148II group). In addition, 143 Caucasian Polish patients with NAFLD were prospectively enrolled in a dietary intervention[22]. All overweight or obese individuals received a 500 kcal restriction diet, whereas patients with normal weight were permitted a dietary intake that was consistent with physiological needs. The total fat content, including mono- and polyunsaturated fats, was reduced to an energy intake of 25%. Additionally, daily cholesterol consumption was less than 300 mg. After 4 mo of the intervention, individuals with the MM genotype of PNPLA3 exhibited a greater improvement in WHR compared to those with the II genotype. In support of the close correlation between WHR and hepatic steatosis[20], decreased WHR facilitates the amelioration of NAFLD on the basis of attenuated abdominal obesity.

Peripheral lipolysis has been identified as the major source of intrahepatocellular triglycerides[24,25], one of the dominant lipid components responsible for hepatic steatosis. Based on the significant correlation between extrahepatic lipolysis and the change in liver fat content[24], the decrease in liver fat following lifestyle modification is attributed to a change in peripheral lipolysis and then FFA delivery to the liver. Using [14C] glycerol, whole-body lipolysis can be analyzed by the rate of appearance (Ra) of glycerol[20]. Enhanced percentage suppression of glycerol Ra increased the anti-lipolytic effect of insulin by the ketogenic diet[20]. PNPLA3-148MM, but not PNPLA3-148II, significantly promoted the suppression of glycerol Ra (37 ± 5% before and 51 ± 4% after the ketogenic diet)[20]. These findings suggest that a greater improvement in the insulin sensitivity of individuals with PNPLA3 148MM compared to those with PNPLA3 148II could have contributed to the greater reduction in liver fat following lifestyle modification.

PHARMACOTHERAPY

NAFLD, with the hallmark of excessive triglyceride accumulation, is considered the hepatic manifestation of the metabolic syndrome (MetS). The co-existence of other MetS components (e.g., dysglycemia, decreased HDL cholesterol and arterial hypertension[26] can also be risk factors for NAFLD severity[27]. Thus, medications associated with glycolipid metabolism (e.g., omega-3 fatty acids, statins, and DPP-4 inhibitors) have been used in the management of NAFLD-related hepatic disorders ranging from steatosis and steatohepatitis to liver fibrosis.

Omega-3 fatty acids

One hundred and three subjects from six hospitals in the south of England were enrolled in a multi-center, double-blind, placebo-controlled clinical trial, "the WELCOME trial", which was performed to test the polymorphism-based therapeutic effects of high-dose omega-3 fatty acids on NAFLD[28]. The primary outcomes were a decrease in percentage liver fat and improvement in liver fibrosis scores. A total of 51 participants block randomized to omega-3 fatty acid ethyl esters, received Omacor® 4 g/d [4 x 1000-mg capsules of 460 mg eicosapentaenoic acid (EPA) and 380 mg docosahexaenoic acid (DHA)] for 15-18 mo. The remaining 52 NAFLD patients were treated with a placebo of isocaloric olive oil (4 g/d) containing approximately 67% oleic acid, 15% linoleic acid, 15% palmitic acid, 2% stearic acid, and 1% alpha linolenic acid. According to the 1H-MRS results, both PNPLA3 148I/I and 148I/M carriers demonstrated an adjusted mean decrease in liver fat percentage (148I/I: -7.05%, 148I/M: -7.30%) following the DHA+ EPA intervention, whereas the PNPLA3 148M/M group had a slight increase in liver fat percentage (2.75%). Moreover, regression modeling demonstrated that the PNPLA3 148 M/M genotype was independently associated with the end-of-study liver fat percentage.

Similar findings were obtained in a randomized controlled trial of DHA supplementation (250 mg/d or 500 mg/d) in obese Italian children with ultrasound-diagnosed NAFLD[29]. As assessed by the combined DHA 250 mg/d and 500 mg/d groups versus placebo group, the 24-mo DHA trial resulted in a decreased probability of severe liver steatosis, with an independent effect of PNPLA3 polymorphism on the response to DHA. Somers' D model of liver fat evaluation revealed that the 148M allele of PNPLA3 predisposes carriers to low treatment response, with a 50% higher probability of more severe steatosis at the end of the trial. In contrast, a greater response to DHA was detected in those who were homozygous for the 148I allele in comparison with heterozygotes. An association between dietary N-6/N-3 polyunsaturated fatty acids (PUFA) ratio and hepatic fat content, and even serum ALT, was previously shown in multiethnic obese children who were homozygous for the 148M PNPLA3 allele[30]. The PNPLA3 148M/M genotype minimizes the secretion of both large TG-rich very-low-density lipoprotein particles and apoB100, and partially decreases lipolytic activity and lysosphosphatidic
acid acyl-CoA transferase activity. Furthermore, it contributes to the distorted fatty acid composition of liver lipid droplets by facilitating the differential incorporation of various types of fatty acids. As a result, human PNPLA3 I148M is thought to be responsible for the abnormal efflux and remodeling, but not the influx of hepatic lipid. Omega-3 PUFAs (N3-PUFAs), including EPA and DHA, exert their pharmaceutical activity on liver fat reduction mainly by inhibiting de novo lipogenesis through SREBP-1c and ChREBP downregulation. Therefore, the PNPLA3 148M allele counteracts the benefit of N3-PUFAs treatment via the limited outflow of liver fat.

**Statins**

With the exception of PUFAs, the interaction between statin use and PNPLA3 genotype on the risk of NASH was investigated in a multicenter cohort (n = 107) of European descent from Italy and Finland. Each subject underwent liver biopsy due to increased liver enzymes, ultrasonographic evidence of steatosis and risk factors, or routine examination during bariatric surgery. Following different types and different intensities of treatment (49% on simvastatin, 27% on rosuvastatin, 17% on atorvastatin, 4% on pravastatin, and 2% on fluvastatin; 15% on high-intensity, 73% on moderate-intensity, and 12% on low-intensity treatment), statins demonstrated dose-dependent protective effect on steatosis, steatohepatitis, and liver fibrosis for at least 6 mo. In support of the findings in the N3-PUFAs intervention, individuals carrying PNPLA3 I148M alleles were susceptible to the full spectrum of liver damage. Statin use was negatively associated with steatohepatitis in patients without PNPLA3 148M variant diagnosed with NAFLD activity score. NASH is characterized by the excessive accumulation of hepatic free cholesterol on the basis of activated 3-hydroxy-3-methyl-glutaryl coenzyme-A reductase (HMGCR), which acts as the rate-limiting enzyme in cholesterol biosynthesis. As HMGCR inhibitors, statins have been linked to a reduced risk of NAFLD in epidemiological studies. Therefore, down-regulation of cholesterol synthesis is thought to underlie the therapeutic effects of statins on NAFLD/NASH. In contrast, PNPLA3 I148M inhibits lipid efflux to abolish the statin-dependent decrease in the hepatic cholesterol pool. This may provide a rational explanation for the blunted benefit of statin treatment in patients with the PNPLA3 148M allele.

**DPP-4 inhibitors**

A 33.1-mo study determined the efficacy of alogliptin (25 mg/d), a selective DPP-4 inhibitor, in 41 biopsy-proven Japanese NAFLD patients with type 2 diabetes mellitus (DM). Of the metabolic and biochemical parameters measured, patients with the G-allele at PNPLA3 rs738409 (genotype CG/GG) showed a positive correlation between improvements in hemoglobin A1c (ΔHbA1c) levels and changes in aminotransferases (ΔALT and ΔAST). It is also worth noting that patients with the CG/GG genotype, instead of the CC genotype, exhibited significantly greater improvements in TC, TG and hyaluronic acid after their intentional weight loss. As effective medications for glucose metabolism, DPP-4 inhibitors (i.e., sitagliptin, alogliptin) have a beneficial impact on HbA1c which depends on the prolonged half-life of glucagon-like peptide 1. The serum level of ALT has been proved to be significantly correlated with increased fasting plasma glucose (FPG), a consequence of abnormal HbA1c. The decrease in HbA1c following DPP-4 inhibitor treatment, especially in patients with high HbA1c (≥7.5%), is positively associated with amelioration of AST and ALT levels. Thus, DPP-4 inhibitors are thought to prevent liver injury, including inflammation and hepatocyte ballooning in NAFLD patients with glucolipid dysmetabolism.
Table 1 Effect of Patatin-like phospholipase domain-containing protein 3 rs738409 C > G p.I148M on therapeutic response in nonalcoholic fatty liver disease

| Study             | Country       | Duration | Number                                   | Intervention                                                                 | Results          |
|-------------------|---------------|----------|------------------------------------------|------------------------------------------------------------------------------|------------------|
| Sevastianova et al (2011) | Finland, Italy | 6 d      | 18 (all in intervention group)           | Hypocaloric (1000-kcal deficit/d), low-carbohydrate diet (< 30 g/d)           | Δliver fat       |
| Shen et al (2015)  | China         | 12 mo    | Intervention group (n = 77), control group (n = 77) | Exercise and limitation on caloric intake                                    | ΔHTGC, ΔBody weight, ΔWC, ΔHbAlc, ΔALT, ΔWHR, ΔHC, ΔHDL-C ΔWHR |
| Milkiewicz et al (2016) | Poland        | 4 mo     | 323 (143 in intervention group; 180 in control group) | Diet with 500 kcal restriction for subjects (BMI > 25); maintance of body weight for subjects (BMI ≤ 25) | Δliver fat       |
| Scorletti et al (2015) | United States | 15-18 mo | Omacor: n = 51; placebo: n = 52           | Drug: simvastatin (49%), rosuvastatin (27%), atorvastatin (17%), pravastatin (4%), fluvastatin (2%) | Δliver fat       |
| Nobili et al (2013) | Italy         | 24 mo    | DHA 250 mg/d (n = 20), DHA 500 mg/d (n = 20), placebo group (n = 20) | Drug: simvastatin (49%), rosuvastatin (27%), atorvastatin (17%), pravastatin (4%), fluvastatin (2%) | Δliver fat       |
| Dongiovanni et al (2015) | Italy, Finland | 6 mo     | 107 (all in intervention group)          | Drug: simvastatin (49%), rosuvastatin (27%), atorvastatin (17%), pravastatin (4%), fluvastatin (2%) | Risk of NASH     |
| Kan et al (2016)   | Japan         | 33.1 mo  | 41 (all in alogliptin group)              | Alogliptin, 25 mg/d                                                          | ΔALT, ΔAST, ΔHbAlc |
| Krawczyk et al (2016) | Spain        | 12 mo    | 84 (all in surgery group)                | Gastro bypass surgery; gastric sleeve surgery                                 | Δweight, Δliver fat |
| Palmer et al (2012) | Sweden        | 2 yr; 10 yr | 3473 (2nd year: 1624 in surgery group; 10th year: 1355 in surgery group) | nonadjustable or adjustable banding; vertical banded gastroplasty; gastric bypass | ΔHOMA-IR, Δserum TG, ΔALT |

*P < 0.05, PNPLA3 148M/M vs PNPLA3 148I/I; †P < 0.05, ‡P < 0.01, among PNPLA3 148I/1, 148I/M, and 148M/M in intervention group; §P < 0.05 PNPLA3 148I/1 +148M/M vs PNPLA3 148M/M; ‡P < 0.01, PNPLA3 148M/M vs PNPLA3 148 I/M and §P < 0.05, PNPLA3 148I/1 vs PNPLA3 148 I/M; ‡P < 0.01, PNPLA3 148I/1 vs 148I/M or PNPLA3 148I/1 vs 148M/M; *ΔHbAlc correlates to ΔALT (P = 0.001) and ΔAST (P = 0.014) in patients with PNPLA3 rs738409 C>G/G; †P < 0.05, ‡P < 0.01, PNPLA3 148I/1 vs PNPLA3 148I/M+148M/M; §P < 0.05, among PNPLA3 148I/1, 148I/M, and 148M/M in surgery group (2nd year); ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; IHTG: Intrahepatic triglyceride content; HbAlc: Hemoglobin A1c; HDL-C: High-density lipoprotein-cholesterol; HOMA-IR: Homeostasis model assessment-insulin resistance; TC: Total cholesterol; TG: Triglycerides; WC: Waist circumference; WHR: Waist-to-hip ratio.

In contrast to the matched control group who underwent nonsurgical treatment (sophisticated lifestyle intervention and behavior modification), the surgery group received one surgical procedure (nonadjustable or adjustable banding, vertical banded gastroplasty, or gastric bypass) at baseline. Weight losses of 25 ± 11%, 16 ± 11%, and 14 ± 14% were documented for gastric bypass, vertical-banded gastroplasty, and banding, respectively, after a 10-year follow-up. PNPLA3 148M carriers showed a greater reduction in homeostasis model assessment-insulin resistance (HOMA-IR) and plasma ALT, together with a lower reduction in triglyceride levels, in comparison with PNPLA3 148I carriers. The prevalence of biopsy-proven hepatic steatosis increased up to 70% in an obese population (BMI ≥30), and even reached 91% in another ultrasound-based study. Multivariate analysis provided deeper insight into the significant association between obese-related steatosis and impairment in both insulin sensitivity (e.g., fasting insulin, HOMA-IR) and glucose metabolism (e.g., FBG). Moreover, the occurrence of steatohepatitis markedly increased with grade of obesity, and was approximately 3% in the lean population, 19% in the obese population, and 50% in the morbidly obese population. Augmentation of serum aminotransferases reflected hepatocyte injury with high sensitivity in these patients with steatohepatitis. In contrast, according to the Diagnosis and Management of NAFLD guideline, weight reduction leads to the amelioration of NAFLD with steatosis resolution, improved HOMA-IR, and normalization of ALT.

An interesting common result in the two above-mentioned studies was the association between PNPLA3 148M and some measured parameters (e.g., liver fat content) which was abolished after weight loss induced by surgery. Marked weight reduction was achieved in both studies (over 30% weight loss after 12 mo in the former; 20%-32% weight loss after 1-2 years and 14%-25% weight loss after 10 yr in the latter), and no NAFLD occurred in the majority of the subjects at the end of the follow-up.
CONCLUSION
Taken together, these results show that PNPLA3 rs738409 has a universal, yet distinctly different, impact on the response to various therapies in NAFLD patients independent of age, gender, and ethnic background. Although the G-allele at PNPLA3 rs738409 (PNPLA3 148M variant) is associated with more severe NAFLD than the C-allele (148I variant), it results in a greater reduction in liver fat following lifestyle modification, bariatric surgery, and pharmacotherapy with DPP-4 inhibitors. The concurrence of weight loss, improved systemic glycolipid metabolism (WHR, TC, TG, LDL, and HbA1c) and decreased intrahepatic fat content highlight an interaction between peripheral adipose tissue and the liver on the actions of the PNPLA3 polymorphism (Table 1). Enhanced systemic insulin sensitivity (e.g., lowered HOMA-IR) with an anti-lipolytic effect and inhibition of periphery-to-liver delivery of FFAs are thought to underlie the benefits of the PNPLA3 rs738409 G-allele over the C-allele. Nevertheless, the hepatoprotective effect, with down-regulated biomarkers of plasma ALT, AST, ALP, and GGT, may not be necessary for the beneficial acquisition.

The risk allele of PNPLA3 rs738409 C > G (PNPLA3 1148M) predisposes NAFLD patients to a poor treatment response to pharmacotherapy (e.g., N3-PUFAs and statins), with increased liver fat percentage and a higher probability of NASH, compared with wild-type PNPLA3 (PNPLA3 148I variant) (Table 1). Both N3-PUFAs, including EPA and DHA, and statins prevent de novo lipogenesis. However, the PNPLA3 148M allele inactivates hepatic glycerolipid hydrolysis due to its “loss-of-function” phenotype and minimizes lipid efflux from the liver to peripheral adipose tissues. This may result in a counteracting mechanism to limit the beneficial effect of pharmacotherapy.

NAFLD is well described to be a complex disease with polymeric association to multiple genes [8]. Limited number of PNPLA3 variant (e.g., rs738409) among these ones has a significant contribution, whereas variants in TM6SF2 [65], MBOAT7 [66] and GCKR [67] show the moderate-size effects. Besides, large number of variants in APOB [68], APOC3 [69], LPL [70], LPL [71], SOD2 [72], UC2 [73], ENPP1 [74], IRS1 [74], IL28B [75], KLF6 [76], MERTK [77], and Irisin [78] action in a low-effect manner. Effect of any risk variant of NAFLD is unlikely to be clinically meaningful. Nonetheless, the variant-dependent difference in treatment response provides prospect for the personalized risk algorithms and therapeutic strategy of NAFLD.

Given the close association of PNPLA3 polymorphism and NAFLD, patients with the G-allele at PNPLA3 rs738409 are thought to benefit from lifestyle modification, DPP-4 inhibitors, and bariatric surgery, which are characterized by weight loss and improved insulin resistance. NAFLD patients carrying the C-allele demonstrate sensitivity to N3-PUFAs and statin treatment. Therefore, stratification of the PNPLA3 rs738409 genotype may serve as a potential approach in the precise treatment of NAFLD.

REFERENCES
1. Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. *Metabolism* 2016; 65: 1017-1025 [PMID: 26997539 DOI: 10.1016/j.metabol.2016.01.012]
2. Nishikawa H, Osaki Y. Liver Cirrhosis: Evaluation, Nutritional Status, and Prognosis. *Mediators Inflamm* 2015; 2015: 872152 [PMID: 26494949 DOI: 10.1155/2015/872152]
3. Pais R, Charlotte F, Fedchuk L, Bedossa P, Lefrarg P, Poynard T, Ratziu V; LIDO Study Group. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. *J Hepatol* 2013; 59: 550-556 [PMID: 23665288 DOI: 10.1016/j.jhep.2013.04.027]
4. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, Chim AM, Yu J, Sung JJ, Chan HL. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. *J Hepatol* 2010; 59: 869-974 [PMID: 20581244 DOI: 10.1111/j.1672-9455.2009.20508X]
5. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemer G, Kechagias S. Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; 44: 865-873 [PMID: 17069293 DOI: 10.1002/hep.21327]
6. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. *J Hepatol* 2018; 68: 268-279 [PMID: 29122391 DOI: 10.1016/j.jhep.2017.09.003]
7. Romero S, Koizilina J, Xing C, Pertsinidis A, Cox D, Pennacchio LA, Boerwinkle E, Cohen JC, Hobbs HH. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. *Nat Genet* 2008; 40: 1461-1465 [PMID: 18820647 DOI: 10.1038/ng.257]
8. Zhang L, You W, Zhang H, Peng R, Zhu Q, Yao A, Li X, Zhou Y, Wang X, Pu L, Wu J. PNPLA3 polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. *J Gastroenterol Hepatol* 2015; 30: 821-829 [PMID: 25641744 DOI: 10.1111/jgh.12889]
9. Lee SS, Byoung YS, Jeong SH, Woo BH, Jang ES, Kim JW, Kim HY. Role of the PNPLA3 1148M polymorphism in nonalcoholic fatty liver disease and fibrosis in Korea. *Dis Med Sci* 2014; 59: 2967-2974 [PMID: 25069572 DOI: 10.1007/s10620-014-3279-z]
10. Kawaguchi T, Sumida Y, Umemura A, Matsuho K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. *PLoS One* 2012; 7: e38332 [PMID: 22719876 DOI: 10.1371/journal.pone.0038322]
11. Baclig MO, Lozano-Kühne JP, Mapua CA, Gomez-Cervantes J, Natividad FF; St Luke’s Liver Diseases Study Group. Genetic variation 1148I in patatin-like phospholipase 3 gene and risk of non-alcoholic fatty liver disease among Filipinos. *Int J Clin Exp Med* 2014; 7: 2129-2136 [PMID: 25233297]
12. Kumari M, Schoiswohl G, Chitraju C, Paar M, Cornaciu I, Rangrez AY, Wongsiriroj N, Nagy HM, Ivanova PT, Scott SA, Knittelfelder O, Recherger GN, Birner-Gruenberger R, Eder S, Brown HA, Haemmerle G, Oberer M, Lass A, Kershaw EE, Zimmermann R, Zechner R. Adiponutrin functions as a nutritionally regulated lysophosphatic acid acyltransferase. *Cell Metab* 2012; 15: 691-702 [PMID: 22560221 DOI: 10.1016/j.cmet.2012.04.008]
13. Huang Y, Cohen JC, Hobbs HH. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. *J Biol Chem* 2011; 286: 37085-37093 [PMID: 21878620 DOI: 10.1074/jbc.M111.290114]
14. Nseir W, Hellou E, Assy N. Role of diet and lifestyle changes in
nonalcoholic fatty liver disease. *World J Gastroenterol* 2014; 20: 9338-9344 [PMID: 25071328 DOI: 10.3748/wjg.v20.i28.9338]

15 Nguyen V, George J. Nonalcoholic Fatty Liver Disease Management. Dietary and Lifestyle Modifications. *Semin Liver Dis* 2015; 35: 318-337 [PMID: 26378647 DOI: 10.1055/s-0035-1562950]

16 Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. *World J Gastroenterol* 2015; 21: 3777-3785 [PMID: 25852263 DOI: 10.3748/wjg.v21.i3.3777]

17 Bower G, Athanasiou T, Isla AM, Harling L, Li JY, Holmes E, Efthimiou E, Darzi A, Ashrafiian H. Bariatric surgery and nonalcoholic fatty liver disease. *Eur J Gastroenterol Hepatol* 2015; 27: 755-768 [PMID: 25091774 DOI: 10.1097/MEG.0000000000000735]

18 Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ; American Gastroenterological Association; American Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology* 2012; 142: 1399-1609 [PMID: 22656328 DOI: 10.1015/j.gastro.2012.04.001]

19 Shen J, Wong GL, Chan HL, Chan RS, Chan HY, Chu WC, Cheung BH, Yeung DK, Li LS, Sea MM, Woo J, Wong VW. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. *J Gastroenterol Hepatol* 2015; 30: 139-146 [PMID: 25040896 DOI: 10.1111/jgh.12656]

20 Sevastianova K, Kotoren A, Gadstaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrarini E, Rissanen A, Olkkonen VM, Yki-Järvinen H. Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. *Am J Clin Nutr* 2011; 94: 104-111 [PMID: 21525193 DOI: 10.3944/ajin.11.012369]

21 Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, Fava JL, Wing RR. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. *Hepatology* 2010; 51: 121-129 [PMID: 19827166 DOI: 10.1002/hep.23376]

22 Krawczyk M, Stachowska E, Milikiewicz P, Lammtfelt F, Milikiewicz M. Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study. *Digestion* 2016; 93: 139-148 [PMID: 26745555 DOI: 10.1159/000441185]

23 Radnai AR, Rahmanian MS, Abrishami A, Yoonessi A, Kooraki T, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Janssen HL, Stricker BH. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. *Eur J Gastroenterol Hepatol* 2015; 27: 26147768 DOI: 10.1111/hepr.12552

24 Kotronen A, Gastaldelli A, Perttilä J, Hakkarainen A, Lundbom J, Suojanen L, Orho-Melander M, Lundbom N, Ferrarini E, Rissanen A, Olkkonen VM, Yki-Järvinen H. Effect of the rs738409 variant of PNPLA3 (adiponutrin) in the liver of patients with non-alcoholic fatty liver disease. *J Hepatol* 2014; 61: 957-960 [PMID: 24074360 DOI: 10.1016/j.jhep.2014.02.002]

25 Novelli V, Bedogni G, Donati B, Aliis A, Valenti L. The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. *J Med Food* 2013; 16: 957-960 [PMID: 24074360 DOI: 10.1089/jmf.2013.0043]

26 Santoro N, Savoye M, Kim G, Marotto K, Shaw MM, Pierpoint B, Caprio S. Hepatic fat accumulation is modulated by the interaction between the rs738409 variant in the PNPLA3 gene and the dietary omega6/omega3 PUFA intake. *PLoS One* 2012; 7: e37827 [PMID: 22629460 DOI: 10.1371/journal.pone.0037827]

27 Pirazzi C, Adiels M, Burza MA, Mancina RM, Levin M, Ståhlan M, Taskinen MR, Orho-Melander M, Pernum J, Pujila A, Anderson L, Maglio C, Montalcini T, Wiklund O, Böer J, Romero S. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M variant is associated with altered hepatic lipid composition in humans. *Diabetologia* 2014; 57: 2103-2107 [PMID: 24972532 DOI: 10.1007/s00125-014-3310-0]

28 Neschens S, Morino K, Dong J, Wang-Fischer Y, Cline GW, Romanelli AJ, Rossbacher JC, Moore IK, Regittng W, Munoz DS, Kim JH, Shulman GL. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-alpha-dependent manner. *Diabetes* 2007; 56: 1034-1041 [PMID: 17251275 DOI: 10.2337/db06-1206]

29 Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaldo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. *J Hepatol* 2015; 63: 705-712 [PMID: 25980762 DOI: 10.1016/j.jhep.2015.05.006]

30 Van Rooyen DM, Larzer CZ, Haigh WG, Yeh MM, Iannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. *Gastroenterology* 2011; 141: 1393-1403, 1403.e1-1403.e5 [PMID: 21703998 DOI: 10.1016/j.gastro.2011.06.040]

31 Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. *Prog Lipid Res* 2013; 52: 175-191 [PMID: 23260728 DOI: 10.1016/j.plipres.2012.11.002]

32 Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanjay AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. *Cell Metab* 2012; 15: 665-674 [PMID: 22560219 DOI: 10.1016/j.cmet.2012.04.004]

33 de Keyser CE, Koehler EM, Schouten JN, Visser LE, Hofman A, Janssen HL, Stricker BH. Statin therapy is associated with a reduced risk of non-alcoholic fatty liver in overweight individuals. *Dig Liver Dis* 2014; 46: 720-725 [PMID: 24815080 DOI: 10.1016/j.dld.2014.04.002]

34 Kan H, Hyogo H, Ochi H, Hotta K, Fukuahara T, Kobayashi T, Naesheiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. *Hepatol Res* 2016; 46: E146-E153 [PMID: 26147768 DOI: 10.1111/hepr.12552]
Treatment for Non-Alcoholic Fatty Liver Disease in a Prospective Long-term outcomes after bariatric surgery: fifteen -year follow -

Impact of bariatric surgery on nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004­2012.

Nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004­2012.

Effects of sitagliptin in diabetic patients with nonalcoholic diabetes mellitus.

Effects of sitagliptin in diabetic patients with nonalcoholic diabetes mellitus.

Implication of PNPLA3 rs738409 underlies treatment response in NAFLD

Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis 2018; 14: 74-80 [PMID: 29056690 DOI: 10.1016/j.soard.2017.09.511]

Dyslipidemia and monitoring of NAFLD in obese patients before and after bariatric surgery. Surg Obes Relat Dis 2016; 12: 137 [PMID: 25164060 DOI: 10.1016/j.soard.2016.06.004]

Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant. PLoS One 2012; 7: e39362 [PMID: 22724004 DOI: 10.1371/journal.pone.0039362]

The hepatic triglyceride concentration in humans by MRE: diagnosis and monitoring of NAFLD in obese patients before and after bariatric surgery. BMC Med 2014; 12: DOI: 10.1186/s12916-014-0137-y

Untargeted comprehensive metabolomics approach for the prediction of PNPLA3-associated NAFLD susceptibility to nonalcoholic fatty liver disease. Hepatology 2016; 64: 2287-2297 [PMID: 26816254 DOI: 10.1002/hep.28105]

Pediadiatric bariatric surgery in morbidly obese adolescents: long-term follow-up. Int J Pediatr Obes 2011; 6 Suppl 1: 65-69 [PMID: 21905519 DOI: 10.3109/17477116.2011.608617]

Long-term outcomes after bariatric surgery: fifteen -year follow -up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann Surg 2013; 257: 87-94 [PMID: 23235396 DOI: 10.1097/SLA.0b013e31827fb6e02]

Impact of bariatric surgery on nonalcoholic fatty liver disease (NAFLD) in morbidly obese patients. Surg Obes Relat Dis 2018; 14: 81-91 [PMID: 29212683 DOI: 10.1016/j.soard.2017.09.005]

Utility of transient elastography (fibroscan) and of bariatric surgery on nonalcoholic fatty liver disease and no­

Novel equation to determine soonthorn V. Type 2 diabetes, impaired fasting glucose, and their association with increased hepatic enzyme levels among the employees in a university hospital in Thailand. J Med Assoc Thai 2009; 92: 961-968 [PMID: 19626817]

Fukuhara T, Hyogo H, Ochi H, Fujino H, Han H, Naeshiro N, Honda Y, Miyaki D, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Efficiency and safety of sitaglitin for the treatment of nonalcoholic fatty liver disease with type 2 diabetes mellitus. Hepatogastroenterology 2014; 61: 323-328 [PMID: 24901133]

Iwasaki T, Yoneda M, Inamori M, Shirakawa J, Higurashi T, Maeda S, Terauchi Y, Nakajima A. Sitaglitin as a novel treatment agent for non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Hepatogastroenterology 2011; 58: 2103-2105 [PMID: 22024083 DOI: 10.5754/hgel1263]

Major P, Pędziwiart M, Rubinkiewicz M, Stanek M, Głuszewska A, Pisarska M, Maleczak P, Budzynski A, Budzynski P. Impact of bariatric surgery on non-alcoholic fatty liver disease. Pol Przegl Chir 2017; 89: 1-4 [PMID: 28537562 DOI: 10.5604/1.3001.0009.6003]

McCarty TR. Echouffo-Tcheugui JB, Lange A, Haque L, Njie B. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liver disease: a nationwide inpatient sample analysis, 2004-2012. Surg Obes Relat Dis 2018; 14: 74-80 [PMID: 29056690 DOI: 10.1016/j.soard.2017.09.511]

Shouhed D, Portillo MP, Aguirre L, Banales JM. PNPLA3 p.1148M variant is associated with greater reduction of liver fat content after bariatric surgery. Surg Obes Relat Dis 2016; 12: 1838-1846 [PMID: 27576208 DOI: 10.1016/j.soard.2016.06.004]

Jefferies FL, Alavi S, Driver N, Boulton AJ, Atif M, Venkatesh NA, Potish S, Santas C, Diamandis EP, Littler MA. Systematic review and meta-analysis of the impact of bariatric surgery on NAFLD. Hepatol Res 2014; 44: 145-159 [PMID: 24261227 DOI: 10.1111/hepr.12111]

Cross-sectional association with increased hepatic enzyme levels among the employees in a university hospital in Thailand. J Med Assoc Thai 2009; 92: 961-968 [PMID: 19626817]
Reilly DF, Castro-Perez J, Kozlitina J, Valenti L, Romeo S. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. *Gastroenterology* 2016; **150**:1219-1230.e6 [PMID: 26850495 DOI: 10.1053/j.gastro.2016.01.032]

67 Petta S, Miele L, Bugianesi E, Cammà C, Rosso C, Boccia S, Cabibi D, Di Marco V, Grimaldo S, Grieco A, Pipitone RM, Marchesini G, Craxi A. Glucokinase regulatory protein gene polymorphism affects liver fibrosis in non-alcoholic fatty liver disease. *PLoS One* 2014; **9**:e87523 [PMID: 24498332 DOI: 10.1371/journal.pone.0087523]

68 Di Filippo M, Moulin P, Roy P, Samson-Bouma ME, Collardeau-Frachon S, Chebel-Dumont S, Peretti N, Dumortier J, Zoulim F, Fontanges T, Parini R, Rigoldi M, Furlan F, Mancini G, Bonnefont-Rousselot D, Bruckert E, Schmitz J, Sozaez JY, Charrière S, Villar-Fimbrel S, Gottrand F, Dubern B, Doummar D, Joly F, Liard-Meillon ME, Lachaux A, Sassolas A. Homozygous MTTP and APOB mutations may lead to hepatic steatosis and fibrosis despite metabolic differences in congenital hypercholesterolemia. *J Hepatol* 2014; **61**:891-902 [PMID: 24842304 DOI: 10.1016/j.jhep.2014.05.023]

69 Zhang RN, Zheng RD, Mi YQ, Zhou D, Shen F, Chen GY, Zha CY, Pan Q, Fan JG. APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases. *Dig Dis Sci* 2016; **61**:2284-2293 [PMID: 27059980 DOI: 10.1007/s10620-016-4210-7]

70 Palmer ND, Musani SK, Yerges-Armstrong LM, Feitosa MF, Bielak LF, Hernanz-R, Kalahi B, Carr JJ, Harris TB, Jhan MA, Kardia SL, Lange AF, Mosley TH JR, Norris JM, Smith AV, Taylor HA, Wagenknecht LE, Liu J, Borecki IB, Peyser PA, Speliotes EK. Characterization of European ancestry nonalcoholic fatty liver disease-associated variants in individuals of African and Hispanic descent. *Hepatology* 2013; **58**:966-975 [PMID: 23564467 DOI: 10.1002/hep.26440]

71 Valenti L, Motta BM, Alisi A, Sartorelli R, Buonaiuto G, Dongiovanni P, Rametta R, Pelusi S, Fargion S, Nobili V. LPIN1 rs13412852 polymorphism in pediatric nonalcoholic fatty liver disease. *J Pediatr Gastroenterol Nutr* 2012; **54**:588-593 [PMID: 22157924 DOI: 10.1097/MPG.0b013e3182442a55]

72 Al-Serri A, Anstee QM, Valenti L, Nobili V, Leathart JB, Dongiovanni P, Patch J, Fracanzani A, Fargion S, Day CP, Daly AK. The SOD2 C477T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. *J Hepatol* 2012; **56**:448-454 [PMID: 21756849 DOI: 10.1016/j.jhep.2011.05.029]

73 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozz Z, Craxi A, Fargion S, Sesti G, Valenti L. The UCP2 -866 G > A promoter region polymorphism is associated with nonalcoholic steatohepatitis. *Liver Int* 2015; **35**:1574-1580 [PMID: 25351290 DOI: 10.1111/liv.12707]

74 Dongiovanni P, Valenti L, Rametta R, Daly AK, Nobili V, Mozz Z, Leathart JB, Pietrobatista A, Tom B, Maggioni M, Fracanzani AL, Lattuada E, Zappa MA, Roviaro G, Marchesini G, Day CP, Fargion S. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. *Gut* 2010; **59**:267-273 [PMID: 20176643 DOI: 10.1136/gut.2009.190801]

75 Petta S, Grimaudo S, Cammà C, Cabibi D, Di Marco V, Licata G, Pipitone RM, Craxì A. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. *J Hepatol* 2012; **56**:1356-1362 [PMID: 22314430 DOI: 10.1016/j.jhep.2012.01.007]

76 Miele L, Beale G, Patman G, Nobili V, Leathart J, Grieco A, Abate M, Friedman SL, Narla G, Bugianesi E, Day CP, Reeves HL. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. *Gastroenterology* 2008; **135**:282-291.e1 [PMID: 18515091 DOI: 10.1053/j.gastro.2008.04.004]

77 Petta S, Valenti L, Marra R, Grimaudo S, Tripodo C, Bugianesi E, Cammà C, Cappon A, Di Marco V, Di Maia G, Dongiovanni P, Rametta R, Gulino A, Mozz Z, Orlando E, Maggioni M, Pipitone RM, Fargion S, Craxì A. MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease. *J Hepatol* 2016; **64**:682-690 [PMID: 26596542 DOI: 10.1016/j.jhep.2015.10.016]

78 Petta S, Valenti L, Svegliati-Baroni G, Ruscica M, Pipitone RM, Dongiovanni P, Ryhlicki C, Ferri N, Cammà C, Fracanzani AL, Pierantonelli I, Di Marco V, Meroni M, Giordano D, Grimaudo S, Maggioni M, Cabibi D, Fargion S, Craxì A. Fibronection Type III Domain-Containing Protein 5 rs34380 A>G Polymorphism, Iron, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *J Clin Endocrinol Metab* 2017; **102**:2660-2669 [PMID: 28472477 DOI: 10.1210/jc.2017-00056]

P- Reviewer: Cardoso CR  S- Editor: Wang JL  L- Editor: A  E- Editor: Tan WW
